Chymopapain-induced hypersensitivity following chemonucleolysis.

Area of Science:

• Immunology
• Allergy Research
• Minimally Invasive Spine Procedures

Background:

• Chemonucleolysis is a procedure utilizing enzymes like chymopapain to treat disc herniation.
• Chymopapain can elicit an immune response, including the production of specific IgE antibodies.
• Monitoring these immune responses is crucial for patient safety and understanding treatment efficacy.

Purpose of the Study:

• To investigate the incidence and patterns of chymopapain-specific IgE antibody development in patients undergoing chemonucleolysis with Chymodiactin.
• To determine if pre-existing chymopapain-specific IgE levels influence post-procedure IgE development.
• To assess changes in IgE levels over a two-month period following the procedure.

Main Methods:

• Utilized the ChymoFAST assay to quantify chymopapain-specific IgE antibody levels.
• Enrolled 91 patients undergoing Chymodiactin chemonucleolysis.
• Collected serum samples for IgE analysis at baseline (pre-chemonucleolysis) and at two months post-procedure.

Main Results:

• 8.8% (17 out of 91) of patients developed chymopapain-specific IgE levels >= 0.06 IU/ml.
• Patients with detectable pre-injection IgE levels showed a significantly higher incidence (36.4%) of developing elevated post-procedure IgE compared to those with undetectable pre-injection levels (4%).
• IgE levels were monitored for two months post-chemonucleolysis.

Conclusions:

• Chemonucleolysis with Chymodiactin can lead to the development of chymopapain-specific IgE antibodies in a subset of patients.
• Pre-existing sensitization to chymopapain is a significant risk factor for developing elevated IgE levels post-chemonucleolysis.
• Further research may be warranted to explore the clinical implications of these IgE changes.